E-viri
Recenzirano
Odprti dostop
-
Kumar, Shaji K., MD; Mikhael, Joseph R., MD; Buadi, Francis K., MD; Dingli, David, MD, PhD; Dispenzieri, Angela, MD; Fonseca, Rafael, MD; Gertz, Morie A., MD; Greipp, Philip R., MD; Hayman, Suzanne R., MD; Kyle, Robert A., MD; Lacy, Martha Q., MD; Lust, John A., MD, PhD; Reeder, Craig B., MD; Roy, Vivek, MD; Russell, Stephen J., MD, PhD; Short, Kristen E. Detweiler, RN, CNP; Stewart, A. Keith, MD; Witzig, Thomas E., MD; Zeldenrust, Steven R., MD, PhD; Dalton, Robert J., MD; Rajkumar, S. Vincent, MD; Bergsagel, P. Leif, MD
Mayo Clinic proceedings, 12/2009, Letnik: 84, Številka: 12Journal Article, Conference Proceeding
Multiple myeloma is a malignant plasma cell neoplasm that affects more than 20,000 people each year and is the second most common hematologic malignancy. It is part of a spectrum of monoclonal plasma cell disorders, many of which do not require active therapy. During the past decade, considerable progress has been made in our understanding of the disease process and factors that influence outcome, along with development of new drugs that are highly effective in controlling the disease and prolonging survival without compromising quality of life. Identification of well-defined and reproducible prognostic factors and introduction of new therapies with unique modes of action and impact on disease outcome have for the first time opened up the opportunity to develop risk-adapted strategies for managing this disease. Although these risk-adapted strategies have not been prospectively validated, enough evidence can be gathered from existing randomized trials, subgroup analyses, and retrospective studies to develop a working framework. This set of recommendations represents such an effort—the development of a set of consensus guidelines by a group of experts to manage patients with newly diagnosed disease based on an interpretation of the best available evidence.
Avtor
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|
Vir: Osebne bibliografije
in: SICRIS
To gradivo vam je dostopno v celotnem besedilu. Če kljub temu želite naročiti gradivo, kliknite gumb Nadaljuj.